There was significant more vascular access thrombosis in the Epo group compared to Darbe group (12 vs. 1.4 %) p < 0.001, and vascular access thrombosis was reported similar in Darbe and Epo groups (10 and 9 %, respectively) in a previous study comparing the efficacy and safety of Darbe to Epo [36]. The gene discussed is EPO; the disease is deep vein thrombosis.